|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, the expression level of CCND1 was significantly upregulated in the PCa tissues and cell lines, which presented negative correlation with the expression of miR-487a-3p.
|
31309555 |
2020 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we identified microRNA-16-5p(miR-16-5p) is significantly upregulated in CaP LNCaP cells following IR and can enhance radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway.
|
30536619 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, these results suggest that miR-501-3p restricts prostate cancer cell growth by targeting CREPT to inhibit the expression of cyclin D1.
|
30621914 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that RCN1 is overexpressed in clinical prostate cancer (PCa) samples, associated with cyclin B, not cyclin D1 expression, compared to that of benign tissues in a Chinese Han population.
|
29453900 |
2018 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As a result, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa according to network topological analysis.
|
29467540 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1.
|
30278884 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, results present that SNHG7 regulates the cycle progression and acts as an oncogenic gene in the prostate cancer tumorigenesis via miR-503/Cyclin D1 pathway, revealing the vital role of lncRNA/miRNA/mRNA axis in prostate cancer carcinogenesis.
|
29571017 |
2018 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-124, STAT3, p-STAT3, Bcl-2 and Cyclin D1 was compared between normal human prostate epithelial cell RWPE-1 and prostate cancer cell DU145.
|
28617558 |
2017 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enforced expression of microRNA-590-3p led to repression of inositol polyphosphate 4-phosphatase type II messenger RNA and protein expression, as well as upregulation of p-Akt, p-FoxO3a, and cyclin D1 and downregulation of p21 expression in prostate cancer cell lines.
|
28345464 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings suggest that the hormone-mediated recruitment of cyclin D1 to sites of DDR may facilitate the resistance of prostate cancer cells to DNA damage therapies and highlight the need to explore other therapeutic approaches in prostate cancer to prevent or overcome drug resistance.
|
26582866 |
2016 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of β-catenin and cyclin D1 in clinical PCa specimens were positively associated with Pin1 expression.
|
26497355 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, our aim was to determine if miR-193b targets cyclin D1 in prostate cancer.
|
26129688 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Numerous epidemiological studies have evaluated the association between the CCND1 A870G polymorphism and the risk of prostate cancer (PCa).
|
25888980 |
2015 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that rottlerin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity with IC(50) values between 0.7 and 1.7 μM for prostate cancer PC-3 and DU145 cells and breast cancer MDA-MB-231 and T-47D cells.
|
24607787 |
2014 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We assessed cyclin D1 expression by conventional immunohistochemistry in 85 patients who underwent radical prostatectomy for prostate carcinoma and 10 normal prostate tissue samples retrieved from autopsies.
|
24820071 |
2014 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
|
24739041 |
2014 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that CCND1 expression is possibly regulated by estrogens via ERβ and that this signaling pathway may influence prostate cancer development.
|
23060014 |
2013 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested whether genetic variations within the CCND1 gene are related to clinical outcomes in prostate cancer patients receiving radical prostatectomy.
|
23354566 |
2013 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the diagnostic value of 3 different genes associated with CaP carcinogenesis, encoding for cell cycle (MDM2, CCND1) and apoptotic (Fas) genes that are differentially expressed in CaP.
|
20822933 |
2012 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concomitantly, BBP treatment decreased the protein levels of phosphorylated retinoblastoma, cyclin D1 and E, cyclin-dependent kinase (CDK) 4 and 2, and pre-replication complex (CDC6 and MCM7) in LNCaP and PC-3 cells, whereas CDK inhibitor p27 was elevated in these cell lines.
|
22067725 |
2012 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer was used as a paradigm because this tumor type is reliant at all stages of the disease on androgen receptor (AR) signaling, and cyclin D1 has been shown to negatively modulate AR-dependent expression of prostate-specific antigen (KLK3/PSA).
|
21212260 |
2011 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also found that CCND1 was dramatically overexpressed both in induced and intrinsically resistant samples of ovarian and prostate cancer.
|
20395447 |
2010 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mining of publicly available human prostate cancer oligoarray datasets revealed that the expression of numerous genes (e.g., CCND1, CD44) under the control of beta-catenin transcription is down-regulated.
|
20454608 |
2010 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.
|
19706803 |
2009 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
|
19079343 |
2009 |